Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Mapping the physical forces that propel proteins forward

31

Mar 2026

Mapping the physical forces that propel proteins forward

Scientists at Oregon Health & Science University have uncovered a previously unknown system of internal "trade winds" that help cells rapidly move essential proteins to the front of the cell, reshaping how researchers understand cell migration, cancer spread and wound healing.

ACLM launches project remission for Type 2 diabetes

31

Mar 2026

ACLM launches project remission for Type 2 diabetes

The American College of Lifestyle Medicine (ACLM) announces the launch of Project Remission: A Lifestyle Medicine Approach to Type 2 Diabetes, a national digital film series developed in partnership with Content With Purpose (CWP).

DNASE1L2 identified as a dynamic biomarker for TB progression

31

Mar 2026

DNASE1L2 identified as a dynamic biomarker for TB progression

Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global population infected with Mycobacterium tuberculosis. While most infections remain latent (LTBI), individuals with LTBI are at risk of progressing to active TB and potentially becoming new sources of transmission.

Uncovering the hidden retinal risks of modern dentistry

31

Mar 2026

Uncovering the hidden retinal risks of modern dentistry

Dentists are exposed to intense lighting for long hours, but its long-term impact on eye health is often overlooked. This study evaluates whether chronic exposure to dental lighting, especially blue and white LEDs, can damage the retina and disrupt its normal function. By combining human data with advanced imaging and animal models, the research uncovers hidden occupational risks and highlights the need for safer lighting practices to help protect dentists' vision.

Using machine learning to scan post-cancer health risks

31

Mar 2026

Using machine learning to scan post-cancer health risks

Artificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support - and the more information included in AI prompting, the better its performance. This finding, published today in Communications Medicine by scientists from St. Jude Children's Research Hospital, may guide future integration of AI into clinical workflows.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.